

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

1

of

4

## Application Number

Unassigned

Filing Date

November 13, 2001

**First Named Inventor**

Levitsky

**Group Art Unit**

1633

Examiner Name

**Sorbello, E.**

Attorney Docket Number

213026

U.S. 10411

09/99243

11/16/01.

[illegible]

**Examiner Signature**

Date Considered

$$\frac{8}{3}$$

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

$+$ 

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Application Number	Unassigned
Filing Date	November 13, 2001
First Named Inventor	Levitsky
Group Art Unit	1633
Examiner Name	Sorbello, E.
Attorney Docket Number	213026

Sheet	2	of	4
-------	---	----	---

[illegible]

in d

8/30/02

- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	Unassigned	
			Filing Date	November 13, 2001	
			First Named Inventor	Levitsky	
			Group Art Unit	1633	
			Examiner Name	Sorbello, E.	
Sheet	3	of	4	Attorney Docket Number	213026

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
L-C	AN	Borrello et al. "Description of a universal GM-CSF-producing bystander cell for use in autologous tumor cell vaccine formulations" <i>Blood</i> , vol. 92 (10), Suppl. 1 part 1-2 (November 15, 1998)		
	AO	Borrello et al. "A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines" <i>Human Gene Therapy</i> , vol. 10, pp. 1983-1991 (August 10, 1999)		
	AP	Clay et al. "Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer" <i>Pathology Oncology Research</i> , vol. 5 (1), pp. 3-15 (1999)		
	AQ	Dranoff et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity" <i>Proc. Natl. Acad. Sci. USA</i> , vol. 90 (8), pp. 3539-3543 (April 1993)		
	AR	Golumbek et al. "Controlled release. Biodegradable cytokine depots: A new approach in cancer vaccine design" <i>Cancer Research</i> , vol. 53, pp. 5841-5844 (December 15, 1993)		
	AS	Huang et al., "Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens" <i>Science</i> , vol. 264, pp. 961-965 (May 13, 1994)		
	AT	Hwang et al. "Prostate cancer vaccines: current status" <i>Seminars in Oncology</i> , vol. 26 (2), pp. 192-201 (April 1999)		
	AU	Jaffee et al., "Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials" <i>Journal of Immunotherapy</i> , vol. 18 (1), pp. 1-9 (July 1995)		
	AV ✓	Klein et al., "Properties of the K562 cell line, derived from a patient with chronic Myeloid leukemia" <i>Int. J. Cancer</i> , vol. 18 (4), pp. 421-431 (October 1976)		
	AW	Levitsky et al., "In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression" <i>J. Exp. Med.</i> , vol. 179 (4), pp. 1215-1224 (April 1994)		
	AX	Levitsky et al., "Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity" <i>The Journal of Immunology</i> , vol. 156 (10), pp. 3858-3865 (May 1996)		
	AY	Lozzio et al., "Human Chronic Myelogenous Leukemia Cell-Line With Positive Philadelphia Chromosome" <i>Blood</i> , vol. 45 (3), pp. 321-334 (March 1975)		
✓	AZ	Mackensen et al. "Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and Interleukin-2 gene transfected fibroblasts" <i>Journal of Molecular Medicine</i> , vol. 75 (4) pp. 290-296 (April 4, 1997)		

Examiner Signature		Date Considered	8/30/02
-----------------------	--	--------------------	---------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

<b>Application Number</b>	<b>Unassigned</b>
<b>Filing Date</b>	<b>November 13, 2001</b>
<b>First Named Inventor</b>	<b>Levitsky</b>
<b>Group Art Unit</b>	<b>1633</b>
<b>Examiner Name</b>	<b>Sorbello, E.</b>
<b>Attorney Docket Number</b>	<b>213026</b>

Sheet	4	of	4
-------	---	----	---

[illegible]

**Examiner  
Signature**

Date  
Considered

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).